Jupiter enters psychedelics space with $100M deal for MDMA drug
Jupiter enters psychedelics space with $100M deal for MDMA drug.
Jupiter Neurosciences
Jupiter Neurosciences is a clinical-stage pharmaceutical company developing treatments for central nervous system (CNS) disorders, with a focus on psychedelic-assisted therapy and neurodegenerative diseases. The company is advancing JNS-101 (MDMA analog) and other CNS-targeting candidates.
Company Info
Sector:Clinical-stage CNS pharmaceuticals
Headquarters:Miami, Florida, United States
Founded:2018
Website:jupiterneurosciences.com
Upcoming Milestones & Key Dates
Q3 2026
Regulatory
MDMA analog IND-enabling studies
Q4 2026
Clinical
First-in-human study design
Clinical Development Pipeline
JNS-101 (MDMA analog)
Target: MDMA receptorJNS-102
Target: Mitochondrial functionJNS-103
Target: Ion channelRecent News
Leadership Team
Chris Bringhurst
Chief Executive Officer
Dianne K. Bryant
Chief Medical Officer
Hollie S. Arnold
Chief Financial Officer